HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

GM237354

a sordarin derivative

Also Known As:

GM 237354

Networked: 6 relevant articles (3 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Indenes: 4
        GM237354: 6
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Indenes: 4
    - GM237354: 6

Experts

1.	Gargallo-Viola, D: 5 articles (10/2001 - 05/2000)
2.	Aviles, P: 4 articles (10/2001 - 05/2000)
3.	Martinez, A: 3 articles (04/2001 - 05/2000)
4.	Falcoz, C: 2 articles (10/2001 - 09/2000)
5.	San Roman, R: 2 articles (10/2001 - 09/2000)
6.	Jimenez, E: 2 articles (04/2001 - 12/2000)
7.	Guillén, M J: 1 article (10/2001)
8.	Gómez De Las Heras, F: 1 article (10/2001)
9.	Regadera, J: 1 article (04/2001)
10.	Santos, I: 1 article (04/2001)

Related Diseases

1.	Infections 04/01/2001 - "In this study, the therapeutic effects of GM237354 were investigated in a novel experimental oral Candida albicans infection model in immunosuppressed rats. " 04/01/2001 - "These results demonstrated that the sordarin derivative GM237354 was effective against experimental oral candidiasis in immunosuppressed rats, and further studies are needed to determine the potential of GM237354 for use in the treatment of this infection in humans." 09/01/2000 - "Area under the concentration-time curve (AUC) and maximum concentration of drug in serum (C(max)) over 24 h were determined after a single GM 237354 subcutaneous (s.c.) dose (50 mg/kg of body weight) in healthy animals (no significant PK changes with infection were observed for other sordarin derivatives). "
2.	Oral Candidiasis (Thrush) 04/01/2001 - "Antifungal efficacy of GM237354, a sordarin derivative, in experimental oral candidiasis in immunosuppressed rats." 04/01/2001 - "These results demonstrated that the sordarin derivative GM237354 was effective against experimental oral candidiasis in immunosuppressed rats, and further studies are needed to determine the potential of GM237354 for use in the treatment of this infection in humans."
3.	Cysts 05/01/2000 - "The three sordarin derivatives tested in vivo-GM 191519, GM 237354, and GM 219771-showed a marked therapeutic efficacy, defined as reduction of cyst forms per gram of lung. " 12/01/2000 - "GM193663 and GM237354 significantly reduced the mean (+/- standard deviation) log number of cysts from 7.6 +/- 0.2 in the untreated group to 4.7 +/- 0.2 and 4.6 +/- 0.1, respectively, when the drugs were administered at a dose of 2 mg/kg/day. "
4.	Systemic candidiasis 09/01/2000 - "A significant correlation between PK parameters and the in vivo activity of GM 237354, taken as a representative FPS inhibitor, was demonstrated in a murine model of lethal systemic candidiasis. " 10/01/2001 - "The antifungal effect of GM 237354, a sordarin derivative, was studied in an in vitro pharmacokinetic (PK)-pharmacodynamic dynamic system (bioreactor) which reproduces PK profiles observed in a previously described model of drug efficacy against murine systemic candidiasis. "
5.	Body Weight (Weight, Body) 10/01/2001 - "Immunocompetent mice infected intravenously with 10(5) CFU of Candida albicans were treated with GM 237354 at 2.5, 10, and 40 mg/kg of body weight every 8 h subcutaneously for 7 days. " 04/01/2001 - "GM237354 was given three times per day for seven consecutive days at 1.25, 2.5, 5, or 10 mg/kg of body weight per dose. " 12/01/2000 - "After a subcutaneous dose of 50 mg/kg of body weight to mice, the maximum level in serum, area under the concentration-time curve, half-life, and clearance for GM193663 and GM237354 were 51.8 and 23 microg/ml, 79.5 and 46 microg. " 09/01/2000 - "Area under the concentration-time curve (AUC) and maximum concentration of drug in serum (C(max)) over 24 h were determined after a single GM 237354 subcutaneous (s.c.) dose (50 mg/kg of body weight) in healthy animals (no significant PK changes with infection were observed for other sordarin derivatives). "

Related Drugs and Biologics

1.	sordarin
2.	Therapeutic Uses
3.	GM193663
4.	Fluconazole (Zonal)
5.	GM211676

Related Therapies and Procedures

1.	Bioreactors (Bioreactor)
2.	Therapeutics